Every Form 4 that Twist Bioscience Corporation (TWST) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TWST and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TWST filings page.
Twist Bioscience Corp (TWST) Chief Financial Officer Adam Laponis sold 2,462 shares of common stock on October 9, 2026, at $156.3049 per share; his directly held position following the sale was 98,114 shares. The shares were sold as required by the issuer’s equity incentive plans to fund tax withholding obligations connected with vesting of Restricted Stock Units. The transaction was not discretionary, and no Rule 10b5-1 plan is reported.
Twist Bioscience Corp (TWST) Chief Executive Officer Emily M. Leproust reported direct sales of 4,548 common shares on October 5, 2026, across eight entries. The entries list weighted-average sale prices from $200.4379 to $207.4556 per share; the sales were made under a Rule 10b5-1 trading plan adopted June 15, 2026. She also reported employee stock options covering 131,290 common shares at a $23.33 exercise price, expiring October 23, 2029, and options covering 64,950 shares at $67.85, expiring August 31, 2030.
Twist Bioscience Corp (TWST) Chief Financial Officer Adam Laponis reported selling 8,057 shares on October 2, 2026, at $188.8840 per share. The shares were required to be sold to cover tax withholding obligations tied to restricted stock unit vesting under the issuer’s equity-plan election; the footnote says the sale was not discretionary. Laponis directly held 100,576 shares after the sale. No Rule 10b5-1 plan is reported.
Twist Bioscience Corp (TWST) reports that SVP of Human Resources Paula Green sold 10,088 shares of common stock on October 2, 2026, at $188.884 per share. Her direct holdings afterward were 106,632 shares. The footnote ties the sale to tax withholding obligations connected with restricted stock unit vesting under the issuer's equity incentive plans.
Twist Bioscience Corp (TWST) President and COO Patrick John Finn reported a sale of 25,714 common shares on October 2, 2026, at $188.8840 per share, leaving him with 185,088 shares. The shares were required to be sold to cover tax withholding on vesting Restricted Stock Units under the issuer’s equity plans; the footnote says these were not discretionary trades. No Rule 10b5-1 plan is reported.
Twist Bioscience Corp (TWST) reported two direct common-stock sales by Chief Executive Officer Emily M. Leproust: 655 shares on October 1, 2026, at $200.0000 per share under a Rule 10b5-1 plan adopted June 15, 2026; and 45,736 shares on October 2, 2026, at $188.8840 per share to cover tax withholding from Restricted Stock Unit vesting. The latter sale was mandated under the issuer’s equity incentive plans and was not discretionary. She also reported options covering 131,290 common shares at a $23.3300 exercise price, expiring October 23, 2029, and 64,950 common shares at a $67.8500 exercise price, expiring August 31, 2030.
Twist Bioscience Corp (TWST) Senior Vice President, Chief Legal Officer and Corporate Secretary Dennis Cho sold 9,514 shares of common stock on October 2, 2026, at $188.8840 per share, leaving 63,789 shares held directly. The shares were sold to cover tax withholding obligations tied to Restricted Stock Unit vesting; the issuer's equity-plan election mandated the sale, which the footnote says was not discretionary. No Rule 10b5-1 plan is reported.
Twist Bioscience Corp (TWST) Chief Accounting Officer Robert F. Werner reported selling 1,482 shares of common stock on October 2, 2026, at $188.8840 per share. The shares were sold to cover tax withholding obligations tied to vesting of restricted stock units under the issuer’s equity incentive plans; the footnote describes these as mandated sell-to-cover transactions, not discretionary trades. Werner held 42,917 shares directly after the sale. No Rule 10b5-1 plan is reported.
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust sold 5,203 shares of common stock in ten transactions on September 24, 2026, under a Rule 10b5-1 trading plan adopted June 15, 2026. The reported weighted-average sale prices and share amounts were 2,485 at $175.2313; 945 at $176.3917; 164 at $177.1699; 330 at $178.6683; 143 at $179.9331; 515 at $180.3911; 21 at $181.4519; 16 at $182.5000; 501 at $183.7641; and 83 at $184.6030 per share.
Twist Bioscience Corp (TWST) Senior Vice President, Chief Legal Officer & Corporate Secretary Dennis Cho sold 348 shares of common stock on September 21, 2026, at $165.4910 per share. The sale covered tax withholding obligations related to vesting of Restricted Stock Units and was required under the issuer’s equity-plan election, rather than a discretionary trade. Cho reported 73,303 shares held directly after the sale. No Rule 10b5-1 plan is reported.
At Twist Bioscience, SVP of Human Resources Paula Green sold 294 common shares at $165.4910 per share on September 21, 2026, leaving her with 116,720 directly held shares. The sale covered tax withholding obligations connected with vesting of Restricted Stock Units. The issuer's equity incentive plan required the “sell to cover” transaction, which the footnote says was not discretionary. No Rule 10b5-1 plan is reported.
Twist Bioscience Corp CEO and director Emily M. Leproust sold 1,687 common shares on September 21, 2026, at $165.4910 per share. The sale was a mandatory “sell to cover” transaction for tax withholding in connection with Restricted Stock Unit vesting, not a discretionary trade; no Rule 10b5-1 plan is reported. She directly held 618,902 common shares after the sale. The filing also lists options covering 131,290 shares at an exercise price of $23.3300 and 64,950 shares at $67.8500.
Twist Bioscience Corp (TWST) reported that Chief Executive Officer and director Emily M. Leproust exercised employee stock options and sold common shares on September 17, 2026 under a Rule 10b5-1 trading plan adopted on June 15, 2026.
She exercised options for 208,708 shares of Common Stock, including 75,439 shares at an exercise price of $8.82 per share expiring September 28, 2027 and 133,269 shares at an exercise price of $26.66 per share expiring November 18, 2028. On the same date she sold 356,546 shares of Common Stock in multiple open-market transactions at weighted average prices per share ranging from approximately $150.77 to $163.60.
Following these transactions, she continues to hold employee stock options directly, including options linked to 131,290 underlying shares at an exercise price of $23.33 per share expiring October 23, 2029 and options linked to 64,950 underlying shares at an exercise price of $67.85 per share expiring August 31, 2030, as reported.
Twist Bioscience Corp (TWST) reported that Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary, sold 412 shares of common stock on September 8, 2026 at $122.62 per share. According to the company’s disclosure, these shares were sold solely to cover tax withholding upon vesting of Restricted Stock Units, and were not discretionary trades. After this transaction, Cho directly held 73,651 shares of Twist Bioscience common stock. No Rule 10b5-1 trading plan is reported for this transaction.
Twist Bioscience Corp (TWST) reported an insider tax-related sale by Paula Green, its SVP of Human Resources. On September 8, 2026, she sold 907 shares of common stock at $122.624 per share. According to the company, this sale was a mandatory "sell to cover" for tax withholding on vesting Restricted Stock Units and was not a discretionary trade. After the transaction, she held 117,014 shares directly.
Twist Bioscience Corp (TWST) reported that Chief Executive Officer and director Emily M. Leproust sold 2,302 shares of Common Stock on September 8, 2026 at $122.624 per share. After this sale, she directly holds 768,427 shares. The sale was required to cover tax withholding on vesting Restricted Stock Units under the company’s equity incentive plans and, according to the disclosure, did not represent a discretionary trade by her. She also holds several employee stock options with exercise prices ranging from $5.95 to $67.85, including performance stock options covering 64,950 underlying shares at a $67.85 exercise price expiring August 31, 2030.
Twist Bioscience Corp (TWST) reported that Chief Accounting Officer Robert F. Werner sold 238 shares of common stock on September 8, 2026, at $122.624 per share. According to the company’s equity incentive plan, this was a mandatory “sell to cover” transaction to satisfy tax withholding on vesting RSUs, not a discretionary trade. After the sale, Werner held 44,399 shares directly.
Twist Bioscience Corp (TWST) reported that Chief Executive Officer and director Emily M. Leproust sold a total of 41,570 shares of common stock on August 25, 2026 in multiple open-market transactions under a previously adopted Rule 10b5-1 trading plan. The reported weighted average sale prices ranged from about $150.56 to $154.45 per share across the trades. Leproust also continues to hold several employee stock option positions, including performance stock options exercisable into 64,950 shares of common stock at an exercise price of $67.85 per share expiring on August 31, 2030.
Twist Bioscience Corp (TWST) reported an insider transaction by Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary. On 2026-08-21, he sold 1,598 shares of common stock at $139.066 per share. A footnote states these shares were sold under a mandated "sell to cover" arrangement to satisfy tax withholding obligations upon vesting of Restricted Stock Units, and are not discretionary trades. Following this transaction, Cho directly held 74,063 shares of Twist Bioscience common stock.
Twist Bioscience Corp (TWST) reported that President and COO Patrick John Finn sold 4,046 shares of common stock on 2026-08-21 at a price of $139.066 per share. According to the company’s equity incentive plan, this was a mandatory “sell to cover” transaction to satisfy tax withholding on vested Restricted Stock Units, not a discretionary trade. After this sale, Finn directly held 210,802 shares, including shares previously acquired under Twist Bioscience’s Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(d) and Rule 16b-3(c).
Twist Bioscience Corp (TWST) reported that officer Paula Green, SVP of Human Resources, had 1,360 shares of common stock sold on 2026-08-21 at $139.066 per share. According to the company’s equity incentive plan, this was a mandatory “sell to cover” transaction to satisfy tax withholding on vesting RSUs, not a discretionary trade. After this tax-related sale, Green directly holds 117,921 shares of Twist Bioscience common stock.
Twist Bioscience Corp (TWST) reported that its Chief Financial Officer, Adam Laponis, sold 1,965 shares of common stock on 2026-08-21 at $139.066 per share. The company states these shares were sold to cover tax withholding obligations upon vesting of Restricted Stock Units, under a mandated "sell to cover" arrangement rather than a discretionary trade. After this tax-related sale, Laponis directly holds 108,633 shares of Twist Bioscience common stock, which include shares acquired through the company’s Employee Stock Purchase Plan.
Twist Bioscience Corp (TWST) reported that Chief Executive Officer and director Emily M. Leproust sold 6,639 shares of common stock on August 21, 2026 at $139.066 per share. According to the company’s equity plan, this mandated “sell to cover” transaction was solely to satisfy tax withholding on vested Restricted Stock Units and was not discretionary. Following the sale, she directly held 812,299 common shares. She also holds several employee stock options with exercise prices ranging from $5.95 to $67.85, including performance stock options with an exercise price of $67.85 expiring August 31, 2030 on 64,950 underlying shares.
Twist Bioscience Corp (TWST) reported that Chief Accounting Officer Robert F. Werner sold a total of 1,523 shares of common stock in two transactions on August 21 and 24, 2026. According to the company’s equity incentive plan, these mandated “sell to cover” transactions were executed solely to fund tax withholding on vested Restricted Stock Units and were not discretionary trades.
Twist Bioscience Corp (TWST) reported that Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary, sold 14,205 shares of common stock on August 19, 2026, at $129.75 per share in an open-market or private transaction. Following the sale, he directly holds 75,661 shares. The transaction was effected under a previously adopted Rule 10b5-1 trading plan dated February 17, 2026.
Twist Bioscience Corp (TWST) reported that President and COO Patrick John Finn exercised a stock option for 23,355 shares of common stock at an exercise price of $67.85 per share, eliminating this option position. On the same date, he sold a total of 78,355 shares of common stock in a series of transactions at weighted-average prices ranging from approximately $115.35 to $122.815 per share. These transactions were effected pursuant to a previously adopted Rule 10b5-1 trading plan dated May 18, 2026.
Twist Bioscience Corp director Katryn Blake reported a sale of 2,240 shares of common stock on August 12, 2026 at $122.88 per share. According to the company’s disclosure, the shares were sold to cover tax liabilities arising from the vesting of Restricted Stock Units pursuant to a prior election and did not represent a discretionary trade. Following this transaction, Blake directly holds 17,208 shares of Twist Bioscience common stock.
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported an option exercise and share sale on August 12, 2026. She exercised 19,952 Employee Stock Options at an exercise price of $26.66 per share, receiving an equal number of common shares. The same day, she sold 19,952 common shares at a weighted average price of $125.0756 per share in transactions executed under a previously adopted Rule 10b5-1 trading plan.
The option exercised relates to a grant expiring on November 18, 2028. Additional stock option holdings are reported with exercise prices of $5.95, $8.82, $23.33, and $67.85, with expirations between 2025 and 2030, showing remaining equity-based incentives.
Twist Bioscience Corp CEO Emily M. Leproust reported an option exercise and share sale under a previously adopted Rule 10b5-1 trading plan. She exercised 113,318 stock options at $26.66 per share into common stock and on the same date sold 113,318 shares at a weighted average price of $125.1615 per share, with individual sale prices ranging from $125.00 to $125.51. The filing also lists several remaining employee stock option awards with exercise prices between $5.95 and $67.85 and expiration dates from 2025 to 2030.
Twist Bioscience Corp director Robert Chess exercised options for 18,417 shares of common stock on August 7, 2026 at an exercise price of $11.89 per share and sold the same 18,417 shares at $110.89 per share. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026. Following these transactions, an entity associated with Chess, the Chess 1997 Trust, held 42,528 shares of common stock indirectly, with Chess and his spouse serving as sole trustees and beneficiaries.
Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp, sold 14,205 shares of common stock on August 5, 2026 at an average price of $109.75 per share. The sale was executed in an open market or private transaction under a pre‑arranged Rule 10b5-1 trading plan adopted on February 17, 2026.
Following this transaction, Cho directly owns 89,866 Twist Bioscience shares.
Twist Bioscience Corp President and COO Patrick John Finn reported a mandated sale of 2,888 shares of common stock on August 3, 2026 at an average price of $85.3212 per share to cover tax withholding from vesting Restricted Stock Units. These shares were sold under a required “sell to cover” election and are not discretionary trades. After this transaction, he directly holds 269,678 shares of common stock.
On August 3, 2026, Paula Green, SVP of Human Resources at Twist Bioscience Corp, sold 1,133 shares of common stock at an average price of $85.3212 per share.
A footnote states these shares were sold under a mandated "sell to cover" arrangement to satisfy tax withholding on vesting Restricted Stock Units and did not represent discretionary trades. Following the sale, she directly holds 119,281 shares.
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported selling 5,101 shares of Common Stock on 2026-08-03 at an average price of $85.3212 per share. According to the disclosure, these shares were sold to cover tax withholding obligations upon vesting of Restricted Stock Units under the company’s equity incentive plans and "do not represent discretionary trades." Following this transaction, Leproust directly holds 818,938 shares of Common Stock and maintains various employee stock options with specified vesting schedules, including performance stock options exercisable at $67.85 per share on 64,950 underlying shares that vested after meeting performance criteria.
Twist Bioscience Corp’s Chief Accounting Officer, Robert F. Werner, sold 167 shares of common stock on 2026-08-03 at $85.3212 per share. According to the company’s equity incentive plans, this mandated “sell to cover” transaction funded tax withholding on vesting Restricted Stock Units and was not discretionary. Following the sale, Werner directly held 46,160 shares.
Twist Bioscience Corp officer Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary, reported a sale of 1,070 shares of common stock on 2026-08-03 at $85.3212 per share. According to the footnote, this mandated "sell to cover" transaction funded tax withholding on vesting Restricted Stock Units and was not a discretionary trade. After the sale, Cho directly held 104,071 shares of common stock.
Twist Bioscience Corp President and COO Patrick John Finn sold 2,238 shares of common stock on July 23, 2026 at $93.893 per share to cover tax withholding from vesting Restricted Stock Units. These mandated "sell to cover" sales were non-discretionary under the company’s equity incentive plans, leaving him with 272,566 directly held shares.
Twist Bioscience Corp Chief Financial Officer Adam Laponis reported an open-market sale of 2,399 shares of common stock on July 9, 2026 at $94.334 per share. According to the disclosure, the sale was required to cover tax withholding obligations arising from the vesting of Restricted Stock Units under the company’s equity incentive plans and did not represent a discretionary trade. After this transaction, Laponis directly holds 110,276 shares of Twist Bioscience common stock.
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported an open-market sale of 18,880 shares of common stock at $95.00 per share on June 25, 2026. After this sale, she directly holds 824,039 common shares. The filing also lists outstanding employee stock options, including 16,470 options exercisable at $8.82 expiring in 2027 and 64,950 options at $67.85 expiring in 2030. The transactions were made under a pre-established Rule 10b5-1 trading plan.
Twist Bioscience Corp officer Dennis Cho reported an open-market sale of Common Stock. On June 24, 2026, Cho sold 14,205 shares at $89.75 per share. After this transaction, he continues to hold 105,141 shares directly.
The filing notes that this sale was carried out under a previously adopted Rule 10b5-1 trading plan dated February 17, 2026, indicating the trade was pre-planned rather than timed at discretion, which often signals routine portfolio management rather than a change in outlook.
Twist Bioscience Corp executive Paula Green, SVP of Human Resources, reported a small mandated share sale tied to equity compensation. On June 22, 2026, she sold 291 shares of common stock at $87.3224 per share solely to cover tax withholding on vesting Restricted Stock Units. After this tax-related transaction, she directly held 120,414 shares of Twist Bioscience common stock.
Twist Bioscience Corp executive Dennis Cho reported a mandated sale of 346 shares of Common Stock. The shares were sold at an average price of $87.3224 per share to cover tax withholding obligations arising from the vesting of Restricted Stock Units under the company’s equity incentive plans.
According to the filing footnote, this was a required "sell to cover" transaction and not a discretionary trade by Cho. Following this tax-related sale, he directly owned 119,346 shares of Twist Bioscience Common Stock.
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported an open-market sale of 1,688 shares of common stock at $87.3224 per share. According to the disclosure, this sale was required to cover tax withholding obligations tied to vesting Restricted Stock Units under the company’s equity incentive plans and was not a discretionary trade.
After this transaction, Leproust directly holds 842,919 shares of Twist Bioscience common stock. She also retains employee stock options covering 64,950 underlying shares at an exercise price of $67.85 per share that are outstanding and expire on August 31, 2030.
Twist Bioscience Corp SVP of Human Resources Paula Green reported option exercises and share sales. On June 15, 2026, she exercised employee stock options for 26,137 shares of common stock at an exercise price of $23.33 per share. The same day, she made open‑market sales of 24,109 shares at a weighted average price of $81.6233 and 2,028 shares at a weighted average price of $82.1655. After these transactions, she directly owned 120,705 shares of Twist Bioscience common stock.
Twist Bioscience Corp officer Dennis Cho reported an open-market sale of 402 shares of common stock at an average price of $69.8442 per share. After this transaction, he directly holds 119,692 shares. According to the disclosure, the sale was mandated to cover tax withholding on vesting Restricted Stock Units under the company’s equity incentive plans and was not a discretionary trade.
Twist Bioscience Corp SVP of Human Resources Paula Green reported a small mandated share sale tied to tax withholding. She sold 884 shares of common stock at an average price of $69.8442 per share to cover taxes due on vesting Restricted Stock Units, under a required “sell to cover” election in the company’s equity incentive plans. After this non-discretionary transaction, she directly holds 120,705 shares.
Twist Bioscience Corp reported that Chief Executive Officer Emily M. Leproust sold 2,265 shares of common stock at $69.8442 per share. According to the disclosure, these shares were sold to cover tax withholding obligations related to vesting Restricted Stock Units under the company’s equity incentive plans, rather than as discretionary trades.
After this tax-related sale, Leproust directly holds 844,607 shares of common stock. She also holds employee stock options to purchase 64,950 shares of common stock at an exercise price of $67.85 per share, which are immediately exercisable and expire on August 31, 2030.
Twist Bioscience Corp's Chief Accounting Officer, Robert F. Werner, reported routine share movements in common stock. On June 8, 2026, he sold a total of 1,359 shares in two open-market transactions at prices of $69.07 and $69.8442 per share.
According to the disclosure, these sales were required to cover tax withholding obligations tied to vesting Restricted Stock Units under the company’s equity plans, and were not discretionary trades. Werner also made a bona fide gift of 500 shares to a charitable organization and continues to hold 46,327 shares directly.
Twist Bioscience Corp officer Dennis Cho reported an open-market sale of 14,205 shares of Common Stock at $69.75 per share. The transaction occurred on May 29, 2026 and was executed under a pre-established Rule 10b5-1 trading plan adopted on May 7, 2025.
After this sale, Cho directly holds 120,094 Twist Bioscience shares, indicating the transaction represents only a portion of his overall ownership. Because the trade was made pursuant to a Rule 10b5-1 plan, its timing reflects a pre-planned arrangement rather than a discretionary decision based on near-term company developments.
Twist Bioscience Corp Chief Financial Officer Adam Laponis reported an open-market sale of common stock. On May 29, 2026, he sold 4,000 shares at a price of $70.00 per share. After the transaction, he directly holds 112,675 common shares. The sale was executed under a previously adopted Rule 10b5-1 trading plan dated May 8, 2025, indicating the trades were pre-scheduled rather than timed at his discretion.